GlobeNewswire Inc | Apr 5, 2021 04:30PM EDT

April 05, 2021

NEW HAVEN, Conn., April 05, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will be held virtually from April 10-15, 2021 and May 17-21, 2021. These presentations will describe the discovery of Arvinas two clinical-stage PROTAC degraders, ARV-110 and ARV-471, including the first disclosures of their structures.

Details for the presentations are as follows:

Title: Discovery of ARV-110, a first in class androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancerDate and Time: April 11, 2021 from 2:05 PM - 2:15 PM ETPresenter: Lawrence B. Snyder, Ph.D., Executive Director of Medicinal Chemistry atArvinasSession Title: New Therapeutics Targeting Molecular Drivers in Cancer

Title: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancerDate and Time: April 11, 2021 from 2:20 PM - 2:30 PM ETPresenter: Lawrence B. Snyder, Ph.D., Executive Director of Medicinal Chemistry atArvinas Session Title: New Therapeutics Targeting Molecular Drivers in Cancer

Abstracts will be available for registered attendees on the AACR website beginning on April 9, 2021.

AboutArvinasArvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the bodys own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC protein degraders against validated and undruggable targets, the company has two clinical-stage programs: ARV-110 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.

Contacts for Arvinas

InvestorsWill OConnor, Stern Investor Relations ir@arvinas.com

MediaKirsten Owens, Arvinas Communicationskirsten.owens@arvinas.com